210 related articles for article (PubMed ID: 32753659)
1. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.
Bae SJ; Cha YJ; Yoon C; Kim D; Lee J; Park S; Cha C; Kim JY; Ahn SG; Park HS; Park S; Kim SI; Jeong J
Sci Rep; 2020 Aug; 10(1):13078. PubMed ID: 32753659
[TBL] [Abstract][Full Text] [Related]
2. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment.
Muñoz-Montaño W; Cabrera-Galeana P; Alvarado-Miranda A; Villarreal-Garza C; Mohar A; Olvera A; Bargallo-Rocha E; Lara-Medina F; Arrieta O
Clin Breast Cancer; 2020 Aug; 20(4):307-316.e1. PubMed ID: 32305297
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting.
Koh YW; Lee HJ; Ahn JH; Lee JW; Gong G
Tumour Biol; 2014 Oct; 35(10):9823-30. PubMed ID: 24986572
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E
BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
[TBL] [Abstract][Full Text] [Related]
7. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
8. The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Dan J; Tan J; Huang J; Zhang X; Guo Y; Huang Y; Yang J
Breast Cancer; 2020 Sep; 27(5):982-988. PubMed ID: 32306184
[TBL] [Abstract][Full Text] [Related]
9. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
[TBL] [Abstract][Full Text] [Related]
10. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
[TBL] [Abstract][Full Text] [Related]
11. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
von Au A; Shencoru S; Uhlmann L; Mayer L; Michel L; Wallwiener M; Hennigs A; Deutsch T; Riedel F; Heil J; Golatta M; Schneeweiss A; Schütz F; Domschke C
Arch Gynecol Obstet; 2023 Apr; 307(4):1105-1113. PubMed ID: 35980458
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy.
Marín Hernández C; Piñero Madrona A; Gil Vázquez PJ; Galindo Fernández PJ; Ruiz Merino G; Alonso Romero JL; Parrilla Paricio P
Clin Transl Oncol; 2018 Apr; 20(4):476-483. PubMed ID: 28785911
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
Patel DA; Xi J; Luo J; Hassan B; Thomas S; Ma CX; Campian JL
Breast Cancer Res Treat; 2019 Apr; 174(2):443-452. PubMed ID: 30604000
[TBL] [Abstract][Full Text] [Related]
16. Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival.
Choi H; Noh H; Cho IJ; Lim ST; Han A
Breast Cancer; 2020 Sep; 27(5):871-879. PubMed ID: 32221862
[TBL] [Abstract][Full Text] [Related]
17. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
18. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
Ding N; Huang J; Li N; Yuan J; Wang S; Xiao Z
BMC Cancer; 2020 Mar; 20(1):235. PubMed ID: 32192443
[TBL] [Abstract][Full Text] [Related]
19. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.
Imamura M; Morimoto T; Egawa C; Fukui R; Bun A; Ozawa H; Miyagawa Y; Fujimoto Y; Higuchi T; Miyoshi Y
Sci Rep; 2019 Feb; 9(1):1811. PubMed ID: 30755651
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
